Eli Lilly (TICKER: LLY) Benchmark And Performance Data

there are 10 of samples in the benchmark for Eli Lilly in year 2022 in 2022. The total inventory for Eli Lilly was $4,458,300,000.00 in 2017. The total inventory for Eli Lilly was $3,980,300,000.00 in 2020. The total inventory for Eli Lilly was $3,886,000,000.00 in 2021. The total inventory for Eli Lilly was $3,561,900,000.00 in 2016. The total inventory for Eli Lilly was $3,445,800,000.00 in 2015. The total inventory for Eli Lilly was $3,190,700,000.00 in 2019. The total inventory for Eli Lilly was $3,098,100,000.00 in 2018. The total inventory for Eli Lilly was $2,928,800,000.00 in 2013. The total inventory for Eli Lilly was $2,740,000,000.00 in 2014. The total inventory for Eli Lilly was $2,643,800,000.00 in 2012. The sales, general, and administrative (SGA) for Eli Lilly was $7,513,500,000.00 in 2012. The sales, general, and administrative (SGA) for Eli Lilly was $7,125,600,000.00 in 2013. The sales, general, and administrative (SGA) for Eli Lilly was $6,620,800,000.00 in 2014. The sales, general, and administrative (SGA) for Eli Lilly was $6,533,000,000.00 in 2015. The sales, general, and administrative (SGA) for Eli Lilly was $6,330,400,000.00 in 2016. The sales, general, and administrative (SGA) for Eli Lilly was $6,180,100,000.00 in 2017. The sales, general, and administrative (SGA) for Eli Lilly was $6,141,900,000.00 in 2021. The sales, general, and administrative (SGA) for Eli Lilly was $6,003,900,000.00 in 2019. The sales, general, and administrative (SGA) for Eli Lilly was $5,869,400,000.00 in 2020. The sales, general, and administrative (SGA) for Eli Lilly was $5,734,600,000.00 in 2018. The sales, general, and administrative (SGA) for Eli Lilly was $$6,067,000,000 in 2022. The revenue volatility for Eli Lilly was 11.74% in 2022. The market capitalization for Eli Lilly was $509,894,916,273.00 in 2021. The market capitalization for Eli Lilly was $445,196,148,280.00 in 2020. The market capitalization for Eli Lilly was $347,613,082,936.00 in 2018. The market capitalization for Eli Lilly was $325,997,273,140.00 in 2019. The market capitalization for Eli Lilly was $308,073,294,870.00 in 2016. The market capitalization for Eli Lilly was $307,239,732,950.00 in 2017. The market capitalization for Eli Lilly was $272,224,753,850.00 in 2015. The market capitalization for Eli Lilly was $263,418,031,660.00 in 2014. The market capitalization for Eli Lilly was $221,019,888,450.00 in 2013. The market capitalization for Eli Lilly was $219,553,094,000.00 in 2012. The market capitalization for Eli Lilly was $$601,576,000,000 in 2022. The gross revenue for Eli Lilly was $28,318,400,000.00 in 2021. The gross revenue for Eli Lilly was $24,539,800,000.00 in 2020. The gross revenue for Eli Lilly was $23,113,100,000.00 in 2013. The gross revenue for Eli Lilly was $22,603,400,000.00 in 2012. The gross revenue for Eli Lilly was $22,319,500,000.00 in 2019. The gross revenue for Eli Lilly was $21,493,300,000.00 in 2018. The gross revenue for Eli Lilly was $21,222,100,000.00 in 2016. The gross revenue for Eli Lilly was $19,973,800,000.00 in 2017. The gross revenue for Eli Lilly was $19,958,700,000.00 in 2015. The gross revenue for Eli Lilly was $19,615,600,000.00 in 2014. The gross revenue for Eli Lilly was $$28,541,000,000 in 2022. The gross margin for Eli Lilly was $30.32% in 2022. The days sales outstanding for Eli Lilly was 87 days in 2022. The days payable outstanding for Eli Lilly was 99 days in 2022. The days of inventory for Eli Lilly was $226 in 2022. The cost of goods sold (COGS) for Eli Lilly was 23.23% in 2022. The cost of goods sold (COGS) for Eli Lilly was $7,312,800,000.00 in 2021. The cost of goods sold (COGS) for Eli Lilly was $5,710,100,000.00 in 2016. The cost of goods sold (COGS) for Eli Lilly was $5,483,300,000.00 in 2020. The cost of goods sold (COGS) for Eli Lilly was $5,037,200,000.00 in 2015. The cost of goods sold (COGS) for Eli Lilly was $4,932,500,000.00 in 2014. The cost of goods sold (COGS) for Eli Lilly was $4,908,100,000.00 in 2013. The cost of goods sold (COGS) for Eli Lilly was $4,796,500,000.00 in 2012. The cost of goods sold (COGS) for Eli Lilly was $4,721,200,000.00 in 2019. The cost of goods sold (COGS) for Eli Lilly was $4,681,700,000.00 in 2018. The cost of goods sold (COGS) for Eli Lilly was $4,447,700,000.00 in 2017. The cost of goods sold (COGS) for Eli Lilly was $$6,630,000,000 in 2022. The cash to cash cycle time for Eli Lilly was 214 in 2022. The annual percentage growth rate of Eli Lilly was -0.01% in 2022. Eli Lilly in its benchmark peer group, had rank 9 for cash to cash cycle time in 2022. Eli Lilly in its benchmark peer group, had rank 9 days for days of inventory in 2022. Eli Lilly in its benchmark peer group, had rank 6 for gross revenue in 2022. Eli Lilly in its benchmark peer group, had rank 5 for sales growth in 2022. Eli Lilly in its benchmark peer group, had rank 4 for cost of goods sold as a percent of revenue in 2022. Eli Lilly in its benchmark peer group, had rank 10 days for days sales outstanding in 2022. Eli Lilly headquarters region is Central. Eli Lilly has ticker symbol LLY. Eli Lilly has the following profile: Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.. Eli Lilly has primary indstury Drug Manufacturers - General. Eli Lilly had a $$8,809,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. Eli Lilly had Organon, and Eli Lilly, and AbbVie, and Pfizer, and Bristol-Myers Squibb, and Amgen, and Gilead Sciences, and Biogen, and Johnson & Johnson, and Merck benchmark peer companies for its SIC code in 2022. Eli Lilly had 97 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. Eli Lilly had 39,000 number of employees in 2022. Eli Lilly had 3.27% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. Eli Lilly had 22 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. Eli Lilly had 132 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. Eli Lilly had 1.39% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. Eli Lilly had 0.81% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. Eli Lilly had 0.01% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. Eli Lilly can reduce overall cost by $$905,000,000 by improving both COGS and SGA to next benchmark tier in 2022. Eli Lilly can reduce inventory with practices including SKU Reduction in 2022. Eli Lilly can reduce inventory with practices including Reduce Manufacturing Latency in 2022. Eli Lilly can reduce inventory with practices including Forecast Accuracy in 2022. Eli Lilly can reduce inventory with practices including Demand Shaping in 2022. Eli Lilly can reduce days sales outstanding with practices including in 2022. Eli Lilly can increase sales revenue by $$8,809,000,000 improving sales performance to next benchmark tier in 2022. Eli Lilly can increase revenue growth by $$3,000,000 by improving growth performance to next benchmark tier in 2022. Eli Lilly can increase overall revenue by $$8,812,000,000 by improving both growth and sales performance to next benchmark tier in 2022. Eli Lilly can increase days payables outstanding with practices including Strategic Sourcing in 2022. Eli Lilly can increase days payables outstanding by $211,000,000 days by increasing days payables outstanding to next benchmark tier in 2022. Eli Lilly can improve total financial performance by $$19,194,000,000 by improving revenue, costs, and working capital in 2022. Eli Lilly can decrease overall working capital by $$9,477,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. Eli Lilly can decrease inventory days by $7,585,000,000 days by reducing inventory days to next benchmark tier in 2022. Eli Lilly can decrease days sales outstanding by $1,681,000,000 days by reducing days sales outstanding to next benchmark tier in 2022. Eli Lilly can accelerate revenue growth practices including Revenue-optimized Planning in 2022. Eli Lilly can accelerate revenue growth practices including Pricing Optimization in 2022. Eli Lilly can accelerate revenue growth practices including Accelerate Design Pipeline in 2022. 82 days was the measured parity or middle performance level for cash to cash cycle time in Eli Lilly's peer group in 2022. 79 days was the measured superior or top ten performance level for days of inventory in Eli Lilly's peer group in 2022. 68 days was the measured advantage or top third performance level for cash to cash cycle time in Eli Lilly's peer group in 2022. 66 days was the measured parity or middle performance level for days sales outstanding in Eli Lilly's peer group in 2022. 61 days was the measured advantage or top third performance level for days sales outstanding in Eli Lilly's peer group in 2022. 6.73% was the measured superior or top ten performance level for sales volatility in Eli Lilly's peer group in 2022. 56 days was the measured superior or top ten performance level for days sales outstanding in Eli Lilly's peer group in 2022. 37.46% was the measured superior or top ten performance level for gross margin in Eli Lilly's peer group in 2022. 37 days was the measured superior or top ten performance level for cash to cash cycle time in Eli Lilly's peer group in 2022. 26.85% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in Eli Lilly's peer group in 2022. 22.98% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in Eli Lilly's peer group in 2022. 21.84% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in Eli Lilly's peer group in 2022. 14.35% was the measured parity or middle performance level for sales volatility in Eli Lilly's peer group in 2022. 129 days was the measured parity or middle performance level for days of inventory in Eli Lilly's peer group in 2022. 100 days was the measured advantage or top third performance level for days of inventory in Eli Lilly's peer group in 2022. 10.93% was the measured advantage or top third performance level for sales volatility in Eli Lilly's peer group in 2022. 0.03% was the measured superior or top ten performance level for sales growth in Eli Lilly's peer group in 2022. 0.00% was the measured advantage or top third performance level for sales growth in Eli Lilly's peer group in 2022. -0.01% was the measured parity or middle performance level for sales growth in Eli Lilly's peer group in 2022. $33.59% was the measured advantage or top third performance level for gross margin in Eli Lilly's peer group in 2022. $30.58% was the measured parity or middle performance level for gross margin in Eli Lilly's peer group in 2022. $$95,482,000,000 was the measured superior or top ten performance level for gross revenue in Eli Lilly's peer group in 2022. $$58,423,000,000 was the measured advantage or top third performance level for gross revenue in Eli Lilly's peer group. $$37,350,000,000 was the measured parity or middle performance level for gross revenue in Eli Lilly's peer group in 2022.